Abstract
Measuring serum thyroglobulin (Tg) levels and anti-Tg antibody is an important modality to monitor patients for recurrence in the follow up of DTC. High anti-Tg antibody levels could make interpretation of Tg levels unreliable and a trend towards increasing anti-Tg antibody levels should prompt additional investigations and potentially additional therapies. It is estimated that up to 10% of the general population can have detectable anti-Tg antibodies. Immunoglobulin therapy such as Octagam®, are sterile preparations of highly purified immunoglobulin G (IgG) derived from large pools of human plasma which leads to passive transfer of antibodies including anti-Tg antibody. Here we present two cases of patients with PTC on IVIG injections with fluctuating anti-Tg antibody levels, making monitoring extremely challenging.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
